Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss - Investor's Business Daily
Eli Lilly earnings beat Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Search Group
Share To
Comments
About Screade
Screade® Inc. version f7eb701, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments